Physician profile
John Robert Absher
NPI 1417949751
$30,221.76
in general payments reported to CMS, 2019-2025
29 companies · $5,384 in 2025
The $5,384 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,459 · 2020: $146 · 2021: $60.21 · 2022: $171 · 2023: $9,514 · 2024: $13K · 2025: $5,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,658 · Consulting Fee: $3,823 · Travel and Lodging: $791 · Food and Beverage: $549 · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,525.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,657.50 |
| Consulting Fee | $3,823.00 |
| Travel and Lodging | $790.82 |
| Food and Beverage | $549.06 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $28,352.66 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $186.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $151.32 | 2019 | |
| Abbvie INC. | $146.59 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $137.48 | 2019-2020 | |
| Biogen, INC. | $134.73 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $129.29 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $119.35 | 2019 | |
| Akcea Therapeutics, INC. | $110.81 | 2019 | |
| Sunovion Pharmaceuticals INC. | $88.25 | 2019 | |
| Merz North America, INC. | $74.46 | 2019 | |
| Alnylam Pharmaceuticals INC. | $65.53 | 2019 | |
| Philips North America LLC | $65.48 | 2019-2020 | |
| Allergan, INC. | $61.87 | 2019-2020 | |
| Emd Serono, INC. | $54.41 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $46.35 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $41.95 | 2019 | |
| Janssen Biotech, INC. | $32.20 | 2025 | |
| Avanir Pharmaceuticals, INC. | $30.32 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $29.55 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $27.96 | 2019 | |
| Amgen INC. | $20.50 | 2019 | |
| Upsher-Smith Laboratories LLC | $19.32 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.70 | 2020 | |
| Bausch Health US, LLC | $14.99 | 2019 | |
| Ucb, INC. | $11.77 | 2019 | |
| Grifols USA, LLC | $11.53 | 2019 | |
| Mdd US Operations, LLC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Absher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.